Active Ingredient Mirvetuximabum Soravtansinum for Ovarian Cancer Therapy
Seeking the supply of the active ingredient Mirvetuximabum Soravtansinum for the medication program B.50 to treat ovarian cancer. Delivery will be to the University Hospital in Szczecin.
CONTRACTING AUTHORITY
Name
UNIWERSYTECKI SZPITAL KLINICZNY NR 2 PUM W SZCZECINIE
City
Szczecin
Country
PL
CLASSIFICATION
Procedure Type
Open Procedure
Contract Type
Supplies
Main CPV
33652100, Antineoplastic agents.
ADDITIONAL DETAILS
EU Funded
Yes
Suitable for SMEs
Yes
Electronic Submission
Required
Legal Basis
32014L0024
DEADLINES & TIMELINE
Submission Deadline
8 days remaining(LOT-0001)
Published